search
Back to results

Autologous Stem Cell Study for Adult TBI (Phase 2b)

Primary Purpose

Brain Injuries, Traumatic, Brain Injuries, Acute, TBI (Traumatic Brain Injury)

Status
Active
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Placebo Infusion
Autologous BMMNC Infusion
Sponsored by
The University of Texas Health Science Center, Houston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Brain Injuries, Traumatic focused on measuring Mesenchymal Stromal Cells, Multipotent, Multipotent Mesenchymal Stromal Cells, Stem Cells, Mesenchymal

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults 18 to 55 years of age on the day of injury,
  2. Non-penetrating closed head trauma.
  3. Glasgow Coma Score between (GCS) between 3 and 8, (best un-medicated post-resuscitation score during screening).
  4. Ability to obtain legally authorized representative consent for participation and complete the BMMNC/Sham harvest and cell/placebo infusion within 48 hours of the initial injury.
  5. Ability to speak English or Spanish.

Exclusion Criteria:

  1. Known history of:

    1. previous brain injury,
    2. intellectual deficiency or psychiatric condition likely to invalidate our ability to assess post-injury changes in cognition or behavior,
    3. neurologic impairment and/or deficit,
    4. seizure disorder requiring anti-convulsant therapy,
    5. recently treated significant infection,
    6. renal disease/altered renal function (post-resuscitation serum creatinine > 1.5 mg/dL),
    7. chronic hepatic disease or altered liver function (post-resuscitation SGPT > 150 U/L, and/or T. Bilirubin >1.3 mg/dL),
    8. cancer,
    9. Chemical or ETOH dependency,
    10. immunosuppression (admission WBC < 3X103),
    11. HIV positive status;
  2. Obliteration of perimesencephalic cistern on initial head CT/MRI suggesting prolonged hypoxic ischemic insult;
  3. Initial hospital ICP > 40 mm Hg;
  4. Hemodynamic instability at the time of screening defined as SBP < 90mmHg, ongoing fluid resuscitation and/or requirement for inotropic support to maintain MAP at or above normals for age - does not include CPP based inotropic support;
  5. Uncorrectable coagulopathy at the time of screening;
  6. Unstable pelvic fractures that in the P.I.'s opinion would preclude the bone marrow / sham harvest;
  7. Pulmonary contusions defined as a chest x-ray with non-anatomic opacification and PaO2:FiO2 ratio < 250 associated with the mechanism of injury;
  8. Greater than AAST Grade III solid or hollow visceral injury of the abdomen and/or pelvis diagnosed by CT or other imaging;
  9. Spinal cord injury diagnosed by CT or MR imaging or by clinical findings;
  10. Persistent hypoxia defined as SaO2 < 94% for > 30 minutes occurring at any time from hospital admission to time of consent;
  11. Positive pregnancy test (if applicable);
  12. Concurrent participation in an interventional drug/device research study;
  13. Unwillingness to return for follow-up visits;
  14. Contraindications to MRI.

Sites / Locations

  • The University of Texas Health Science Center at Houston

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Autologous BMMNC Infusion

Placebo Infusion

Arm Description

Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.

Subjects randomized to the placebo control group will undergo a "sham" bone marrow harvest.

Outcomes

Primary Outcome Measures

Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.
Subjects will undergo three 3T-MRI evaluations. The first will occur 7 to 10 days after hospitalization, when clinically stable. The following five pulse sequences constitute a complete imaging session: 1) conventional localizer/scout 2) 3D isotropic T1-weighted MPRAGE 3) 3D isotropic T2-weighted TSE 4) 32-direction single-shot spin-echo diffusion sensitized echo-planar (DTI-32dir) 5) 3D-FLAIR. The 3T-MRI will be repeated at 1 and 6 months post-injury. Composite scores will be calculated for comparison.

Secondary Outcome Measures

Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.
Group differences in functional and neuropsychological outcomes will be assessed. Outcome scores will be correlated with specific macrostructural and microstructural metrics from the MRI. Composite scores will be calculated for comparison.
Compare neuro-inflammatory biomarkers between groups..
CSF and plasma samples will be analyzed for neuro-inflammatory biomarkers and comparisons made between groups.
Measure the number of participants with infusion related adverse events.
Infusion related adverse events will be determined from analysis of standard of care ICU monitoring data and comparisons made between groups.
Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.
Spleen ultrasound volume will be measured. A comparison of results between groups will help in understanding the contribution of the spleen in the systemic inflammatory responses after acute TBI.
Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).
Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs.
Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.
Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs.
Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.
Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs.

Full Information

First Posted
March 23, 2015
Last Updated
July 15, 2023
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
United States Department of Defense, U.S. Army Medical Research and Development Command
search

1. Study Identification

Unique Protocol Identification Number
NCT02525432
Brief Title
Autologous Stem Cell Study for Adult TBI (Phase 2b)
Official Title
A Multicenter Trial of Autologous Bone Marrow Mononuclear Cells for the Treatment of Adult Severe Traumatic Brain Injury
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 21, 2016 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston
Collaborators
United States Department of Defense, U.S. Army Medical Research and Development Command

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the effect of intravenous infusion of autologous bone marrow mononuclear cells (BMMNC) on brain structure and neurocognitive/functional outcomes after severe traumatic brain (TBI) injury in adults. The primary objective is to determine if the intravenous infusion of autologous BMMNC after severe TBI results in structural preservation of global gray matter (GM) volume and white matter (WM) volume and integrity; as well as select regions of interest in the corpus callosum. THe secondary objectives are to determine if autologous BMMNC infusion improves functional and neurocognitive deficits in adults after TBI; reduces the neuroinflammatory response to TBI; evaluate spleen size and splenic blood flow over time using ultrasound and corresponding changes in inflammatory cytokines; and infusion related toxicity and long-term follow-up safety evaluations.
Detailed Description
Traumatic brain injuries are associated with 33% of all trauma related deaths. There are no effective therapies to treat secondary brain injury and the post-injury response of CNS apoptosis and neuroinflammation. Pre-clinical and Phase I clinical progenitor cell therapies have shown promise in TBI/stroke via (1) promotion of CNS structural preservation, and (2) reducing the neuroinflammatory response to injury. This is a multicenter, randomized, blinded, Bayesian CRM dose-escalation placebo-controlled study designed to treat severe, acute TBI in adult patients with an IV infusion of autologous bone marrow mononuclear cells. 55 adult TBI patients will be randomized to receive a single IV infusion of BMMNs (6 x 10^6 or 9 x 10^6) or placebo. Study subjects will be consecutive admissions of adults with severe TBI meeting inclusion/exclusion criteria. Adults, ages 18-55 years, hospitalized at Memorial Hermann Hospital (Houston, Texas) for severe TBI (GCS 3-8) will be screened for eligibility. Informed consent, the bone marrow/sham harvest, and stem cell/placebo infusion must take place within 48 hours of the initial injury. Following consent and baseline procedures, subjects will be randomized in a 3:2 ratio (using permuted blocks and stratified by GCS of 3-4 or 5-8) to autologous BMMNC infusion (n=33) and placebo (n = 22), respectively. Administration will begin with the lowest dose (i.e. 6 x 10^6 cells/kg body weight) with each dose given to cohorts of 3 subjects treated with BMMNC (note: the cohort size refers only to subjects treated with autologous BMMNC). After each cohort of 3 subjects treated with autologous BMMNC infusion (accumulated on average after every 5.5 adults randomized), the dosage for the next cohort of 3 autologous BMMNC-treated subjects will be determined by the CRM based on the findings for all subjects previously treated and the prior probabilities of the likelihood of toxicity assigned by the investigators before starting the study. At all doses, the algorithm is designed to avoid administering doses that will have a p(toxicity) exceeding 0.15. Subjects will be monitored closely for infusion related toxicity and complications during the first 14 days post-infusion while also receiving the usual standard of care for traumatic brain injury . Safety and outcome assessments will be performed at 1, 6, and 12 months post-injury study visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Injuries, Traumatic, Brain Injuries, Acute, TBI (Traumatic Brain Injury)
Keywords
Mesenchymal Stromal Cells, Multipotent, Multipotent Mesenchymal Stromal Cells, Stem Cells, Mesenchymal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
37 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Autologous BMMNC Infusion
Arm Type
Experimental
Arm Description
Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.
Arm Title
Placebo Infusion
Arm Type
Placebo Comparator
Arm Description
Subjects randomized to the placebo control group will undergo a "sham" bone marrow harvest.
Intervention Type
Biological
Intervention Name(s)
Placebo Infusion
Intervention Description
In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
Intervention Type
Biological
Intervention Name(s)
Autologous BMMNC Infusion
Other Intervention Name(s)
Stem Cell Infusion
Intervention Description
In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
Primary Outcome Measure Information:
Title
Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.
Description
Subjects will undergo three 3T-MRI evaluations. The first will occur 7 to 10 days after hospitalization, when clinically stable. The following five pulse sequences constitute a complete imaging session: 1) conventional localizer/scout 2) 3D isotropic T1-weighted MPRAGE 3) 3D isotropic T2-weighted TSE 4) 32-direction single-shot spin-echo diffusion sensitized echo-planar (DTI-32dir) 5) 3D-FLAIR. The 3T-MRI will be repeated at 1 and 6 months post-injury. Composite scores will be calculated for comparison.
Time Frame
up to 6 months. Post Head Injury
Secondary Outcome Measure Information:
Title
Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.
Description
Group differences in functional and neuropsychological outcomes will be assessed. Outcome scores will be correlated with specific macrostructural and microstructural metrics from the MRI. Composite scores will be calculated for comparison.
Time Frame
Changes From Baseline to 6 mo. Post Head Injury
Title
Compare neuro-inflammatory biomarkers between groups..
Description
CSF and plasma samples will be analyzed for neuro-inflammatory biomarkers and comparisons made between groups.
Time Frame
Changes From Baseline to 6 mo. Post Head Injury
Title
Measure the number of participants with infusion related adverse events.
Description
Infusion related adverse events will be determined from analysis of standard of care ICU monitoring data and comparisons made between groups.
Time Frame
up to 6 mo. Post Head Injury
Title
Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.
Description
Spleen ultrasound volume will be measured. A comparison of results between groups will help in understanding the contribution of the spleen in the systemic inflammatory responses after acute TBI.
Time Frame
up to 6 mo. Post Head Injury
Title
Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).
Description
Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs.
Time Frame
1 yr. Post Head Injury
Title
Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.
Description
Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs.
Time Frame
1 yr. Post Head Injury
Title
Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.
Description
Brain PET and DT-MRI imaging will be obtained 1yr post injury. The outcome measures will be PET-MRI imaging SUV (standardized uptake values) based upon injected dose per patient weight. Voxel-wise analysis of regions of interest (ROI) will focus on: Midbrain, thalamus, hippocampus and cortical subdivisions which will be compared over time and to imaging data from healthy volunteers (enrolled under a different protocol). The SUV in ROIs will be correlated with a battery of functional outcomes measures focusing on the NINDS Common Data Elements. The degree of microglial activation will be correlated with the degree of volumetric loss in specific ROIs.
Time Frame
1 yr. Post Head Injury

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults 18 to 55 years of age on the day of injury, Non-penetrating closed head trauma. Glasgow Coma Score between (GCS) between 3 and 8, (best un-medicated post-resuscitation score during screening). Ability to obtain legally authorized representative consent for participation and complete the BMMNC/Sham harvest and cell/placebo infusion within 48 hours of the initial injury. Ability to speak English or Spanish. Exclusion Criteria: Known history of: previous brain injury, intellectual deficiency or psychiatric condition likely to invalidate our ability to assess post-injury changes in cognition or behavior, neurologic impairment and/or deficit, seizure disorder requiring anti-convulsant therapy, recently treated significant infection, renal disease/altered renal function (post-resuscitation serum creatinine > 1.5 mg/dL), chronic hepatic disease or altered liver function (post-resuscitation SGPT > 150 U/L, and/or T. Bilirubin >1.3 mg/dL), cancer, Chemical or ETOH dependency, immunosuppression (admission WBC < 3X103), HIV positive status; Obliteration of perimesencephalic cistern on initial head CT/MRI suggesting prolonged hypoxic ischemic insult; Initial hospital ICP > 40 mm Hg; Hemodynamic instability at the time of screening defined as SBP < 90mmHg, ongoing fluid resuscitation and/or requirement for inotropic support to maintain MAP at or above normals for age - does not include CPP based inotropic support; Uncorrectable coagulopathy at the time of screening; Unstable pelvic fractures that in the P.I.'s opinion would preclude the bone marrow / sham harvest; Pulmonary contusions defined as a chest x-ray with non-anatomic opacification and PaO2:FiO2 ratio < 250 associated with the mechanism of injury; Greater than AAST Grade III solid or hollow visceral injury of the abdomen and/or pelvis diagnosed by CT or other imaging; Spinal cord injury diagnosed by CT or MR imaging or by clinical findings; Persistent hypoxia defined as SaO2 < 94% for > 30 minutes occurring at any time from hospital admission to time of consent; Positive pregnancy test (if applicable); Concurrent participation in an interventional drug/device research study; Unwillingness to return for follow-up visits; Contraindications to MRI.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles S Cox, MD
Organizational Affiliation
UTHealth McGovern Medical School, Houston, TX
Official's Role
Principal Investigator
Facility Information:
Facility Name
The University of Texas Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Data will be reported in aggregate.

Learn more about this trial

Autologous Stem Cell Study for Adult TBI (Phase 2b)

We'll reach out to this number within 24 hrs